Voyager Therapeutics (VYGR) Receives a Buy from Canaccord Genuity

In a report issued on December 22, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Voyager Therapeutics (VYGR), with a price target of $14.00. The company’s shares closed last Tuesday at $8.69.

According to, Kulkarni is a 5-star analyst with an average return of 22.7% and a 53.6% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Zynerba Pharmaceuticals.

Voyager Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $12.67.

See today’s analyst top recommended stocks >>

Voyager Therapeutics’ market cap is currently $325.6M and has a P/E ratio of 8.10. The company has a Price to Book ratio of 1.90.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts